Emergent BioSolutions (EBS) Capital Expenditures (2010 - 2026)

Emergent BioSolutions' Capital Expenditures history runs 17 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 33.33% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $400000.0, a 98.28% decrease from a year earlier, with the FY2025 full-year figure at $1.6 million, down 93.01% from the prior year.
• Capital Expenditures improved to $2.4 million in Q1 2026 per EBS's latest filing, from -$200000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $42.4 million in Q4 2023 and bottomed at -$82.8 million in Q4 2022.
• The 5-year median for Capital Expenditures is $3.6 million (2025), against an average of $5.2 million.
• Biggest YoY gain for Capital Expenditures was 4112.5% in 2022; the steepest drop was 514.0% in 2022.
• Year by year, Capital Expenditures stood at -$82.8 million in 2022, then soared by 151.21% to $42.4 million in 2023, then tumbled by 95.99% to $1.7 million in 2024, then slumped by 111.76% to -$200000.0 in 2025, then soared by 1300.0% to $2.4 million in 2026.
• Per Business Quant, the three latest EBS Capital Expenditures figures stand at $2.4 million (Q1 2026), -$200000.0 (Q4 2025), and -$4.7 million (Q3 2025).